Empagliflozin or Glimepiride for Type 2 Diabetes
Treatments studied
Part of Hormones & metabolism clinical trials.
This trial compares two diabetes medications, empagliflozin and glimepiride, added to your current treatment to see which is more effective and safe for managing blood sugar. It is for adults with type 2 diabetes who have already been on oral diabetes pills for at least 8 weeks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult 19 years or older.
- You have been diagnosed with type 2 diabetes.
- You have been taking oral diabetes medications for at least 8 weeks.
- You do not have type 1 diabetes or diabetes caused by another condition.
- You do not have severe diabetes complications like eye disease related to diabetes.
- You have not used any insulin for more than 7 days in the last 12 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding empagliflozin (a diabetes pill) to your current medicines (alogliptin and metformin) helps manage blood sugar better. It may be an option if your blood sugar is not well controlled with your current treatment.
This trial tests a medication called empagliflozin (a type 2 diabetes pill) to see how well it works in people with type 2 diabetes who have not taken any diabetes drugs for at least 8 weeks. If you qualify, you may receive the study drug and help researchers learn more about managing blood sugar.
This study is testing two different diabetes pills—dapagliflozin or pioglitazone—in people with type 2 diabetes. The goal is to see which one works better when added to your current metformin and DPP-4 inhibitor. You may qualify if your blood sugar is not well controlled with your current medications.
This trial tests a combination of three common diabetes medications (metformin, an SGLT2 inhibitor, and a TZD) to see how well they work together and if they are safe. It may help people with type 2 diabetes who need better blood sugar control.
This trial tests enavogliflozin (a newer SGLT2 inhibitor) compared to older drugs (dapagliflozin or empagliflozin) to see how well it protects the heart and kidneys in people with type 2 diabetes.
This study tests a new diabetes medicine called Enavogliflozin against an older drug, Pioglitazone, to see which works better for lowering blood sugar and improving heart health. If you have type 2 diabetes, take metformin plus another pill, and your A1C is between 7 and 10.5, this study may be an option for you.
Hear when a new Diabete Type 2 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.